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Alzheimer’s disease (AD) is a neurodegenerative disorder 
affecting multiple clinical domains involving cognitive 
functioning, behavioral aspects, and functional-physical 
skills.1 In the past 15 years, the growing social emergency 
represented by AD and the lack of medical treatments able 
to modify the disease course have kindled the interest in 
nonpharmacological therapies. This term, often used to 
describe the array of approaches and techniques proposed 
in the literature, spans several domains (cognitive-oriented 
therapies, physical medicine, etc). Another term used to 
indicate these kinds of approaches is psychosocial thera-
pies, but this word seems to exclude the possibility that 
these therapies can modify brain function or structure. 
Hence, some authors have proposed modified versions 
such as biopsycosocial or psychobiosocial therapies.2,3 
Functional magnetic resonance imaging (fMRI), due to its 
capacity to monitor neural circuits reorganization, has 
been recently introduced to evaluate the efficacy of these 
nonpharmacological treatments (see Cramer et al4 for a 
review), also including treatments for amnestic mild cog-
nitive impairment (MCI)5 and AD.6
Cognitive stimulation (CS) is probably the most wide-
spread and well-studied technique in this field, but it is still 
a matter of debate whether this therapy is able to slow down 
the disease course.7 The most defined form is cognitive 
stimulation therapy (CST), which incorporates the positive 
aspects of reality orientation therapy but avoids putting the 
person with dementia in stressful situations and implements 
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Abstract
Background. The growing social emergency represented by Alzheimer’s disease (AD) and the lack of medical treatments 
able to modify the disease course have kindled the interest in nonpharmacological therapies. Objective. We introduced 
a novel nonpharmacological approach for people with AD (PWA) named Multidimensional Stimulation group Therapy 
(MST) to improve PWA condition in different disease domains: cognition, behavior, and motor functioning. Methods. 
Enrolling 60 PWA in a mild to moderate stage of the disease, we evaluated the efficacy of MST with a randomized-
controlled study. Neuropsychological and neurobehavioral measures and functional magnetic resonance imaging (fMRI) 
data were considered as outcome measures. Results. The following significant intervention-related changes were observed: 
reduction in Neuropsychiatric Inventory scale score, improvement in language and memory subscales of Alzheimer’s 
Disease Assessment Scale–Cognitive subscale, and increased fMRI activations in temporal brain areas, right insular cortex, 
and thalamus. Conclusions. Cognitive-behavioral and fMRI results support the notion that MST has significant effects in 
improving PWA cognitive-behavioral status by restoring neural functioning.
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stimulation in a respectful and person-centered manner.8 In 
2003, Spector and colleagues9 showed that this approach 
was at least as effective as cholinesterase inhibitors to 
reduce cognitive decline. On the basis of this work, the 
2006 NICE guidelines concluded that this intervention 
should be routinely proposed to people with mild to moder-
ate dementia.10 Recently, a maintenance protocol with CST 
was developed with a very precise procedure that involved 
not only professionals but also people with dementia and 
their caregivers.11 It seems that CST was able to change 
some aspects of cognition, especially those related to lan-
guage and memory, more than others.12,13 In a Cochrane 
review on CS,14 the authors found a consistent benefit on 
cognitive function that persisted at follow-up 1 to 3 months 
after the end of the treatment. In secondary analyses with 
smaller total sample sizes, improvements were also 
observed on self-reported quality of life and well-being.
In the past years, further nonpharmacological therapy 
studies have allowed for firmer conclusions to be drawn 
on their efficacy. Occupational and recreational therapy, 
for example, can reduce psychobehavioral disturbances 
of people with dementia, increase their participation, 
improve their quality of life, reduce negative communica-
tion, extend the caregiver sense of competence, and 
reduce his/her burden.15,16 Moreover, exercise has been 
shown to improve the physical health and the well-being 
of people with dementia17 and appeared to be beneficial 
in reducing behavioral and psychological symptoms of 
dementia (BPSD).18 Interestingly, aerobic exercise train-
ing in adults seems to promote an improvement in spatial 
memory and to reverse age-related loss in volume by 1 to 
2 years.19 In Belgium and the Netherlands, psychomotor 
therapy has been well integrated into mental health care 
since 1965.20
Based on this growth of evidence, some research groups 
have therefore decided to propose multidimensional proto-
cols of treatment for people with AD (PWA), based on the 
hypothesis that this type of approach would be the most suit-
able to improve their condition in different disease domains: 
cognition, behavior, and motor functioning. This kind of 
therapy would be also the most appropriate for the unique 
profile of each person with AD, even when performed in 
small groups.21,22 In the past 13 years, our group has devel-
oped a multidimensional approach—Multidimensional 
Stimulation Therapy (MST). Our previous findings23-25 sup-
port the notion that this group activity program, based on 
cognitive stimulation, recreational-occupational activities, 
and physical-psychomotor exercises, can lead to an improve-
ment in behavioral aspects for PWA.
In this article, we describe a randomized single-blind 
trial aimed to clarify the efficacy of an MST program in 
outpatients affected by AD in mild to moderate stages of the 




Sixty participants were consecutively recruited from the 
Don Gnocchi Foundation Memory Clinic.
Outpatients eligibility criteria were the following: (a) 
diagnosis of probable AD according to NINCDS-ADRDA 
criteria1; (b) evidence of AD pathophysiological processes 
detected with structural MRI as a biomarker of neural injury1; 
(c) mild to moderate stage of AD (Mini-Mental State 
Examination (MMSE) score of 15-24 [see Magni et al26] and 
Clinical Dementia Rating scale score of 1-2 [see Hughes et 
al27]); (d) age range 65 to 85 years and school attendance 
range 5 to 17 years; (e) right handedness as assessed by the 
Edinburgh inventory.28 PWA were excluded if they had (a) 
severe aphasia (Token test score < 20 [see Spinnler and 
Tognoni29]) or severe auditory and/or visual loss; (b) overt 
severe behavioral disturbances that could hinder the MST 
session; and (c) recent (3 months before the MST) introduc-
tion or dose modification of the following pharmacological 
treatments: cholinesterase inhibitor, memantine, antidepres-
sant, or antipsychotic drugs. Low-dose benzodiazepines for 
insomnia were allowed during the study.
Each patient had a caregiver who supervised treatment 
compliance.
Demographic, neuropsychological, and anatomical 
details are shown in Table 1.
According to a previous multicenter controlled study,25 
sample size calculation was performed considering an 
effect size of 1.7 and a standard deviation of 2.8 of primary 
outcomes differences between groups. Under the assump-
tion of normal distribution of the scores and considering an 
α level of .05, a sample size of 30 subjects resulted in a 
power greater than 70% and was thus believed to be ade-
quate for this trial.
Moreover, 22 healthy controls (HC) who were age-
matched and sex-matched to the PWA (73.2 ± 5.1 years; 8 
males/14 females; MMSE score >28) were also included in 
the fMRI analysis for the description of the typical activa-
tion pattern and for the definition of regions of interest to be 
used for the analyses on PWA data.
The study was approved by the Ethics Committee of 
Don Gnocchi Foundation, and informed written consent 
was obtained from all the included subjects and their care-
givers (or a legally acceptable representative if applicable 
and if different from the caregiver) before study initiation.
The trial was registered at www.clinicaltrials.gov 
(NCT01893398).
Randomization and Masking
The target population was stratified by gender and ran-
domly assigned (1:1 ratio) to MST (tMST) or a usual care 
program (no stimulation treatment, ntMST) in a single-blind 
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parallel-group study. Randomization was conducted by an 
independent operator, who was not involved in assessment 
and treatment using a computer algorithm (http://graphpad.
com). Participants and their caregivers were instructed not to 
discuss the nature of their therapy with the research assistants 
who did the assessments. Outcome measures were collected 
by researchers blinded to group allocation.
Intervention
The MST program involved 3 levels of treatment. The 
first level was focused on PWA, the second level involved 
the caregiver, whereas the third one included the dyad 
PWA–caregiver.
Level 1—PWA. The PWA performed 30 rehabilitation ses-
sions (2.5 hours a day, 3 days a week) in a room with a 
kitchen area, table and chairs, and materials necessary to 
carry out recreational–occupational activities. MST was 
administered by a psychologist and a rehabilitation thera-
pist, both specialized in cognitive rehabilitation. Tight inter-
action between participants and therapists was an essential 
feature of our program: as previously noted,30 an attractive 
environment or the mere presence of the staff is insufficient 
to evoke in PWA the exercise of their full functional capaci-
ties. The treatment involved 4 steps: (a) Reality Orientation 
activities and cognitive exercises (about 45-minute); (b) 
physical activity (about 30-minute); (c) occupational activi-
ties of daily living (about 30-minute); (d) recreational activ-
ities (about 45- minute).
Level 2—Caregiver. All caregivers of PWA had a single sup-
port interview with a psychologist at the beginning and at 
the end of the training. In these moments, family caregivers 
could freely express their psychological sufferance and 
their practical difficulties. Caregivers also followed 
a standardized short group educational program with a 
rehabilitation therapist. The program touched on several 
points: AD clinical picture, pathogenetic mechanism, phar-
macological therapy and recent advances in research, cop-
ing with behavioral problems, as well as legal and social 
aspects. The second level was offered (a) to collect data 
about past preferences and personality of the PWA in order 
to integrate this information into the rehabilitation program; 
(b) to offer psychological support to the caregiver; and (c) 
to promote the detection of practical coping solutions. 
Moreover, during psychoeducational meetings, caregivers 
were trained by the therapist in order to continue the treat-
ment at home (see Level 3).
Level 3—Dyad PWA and Caregiver. All subjects performed 
further stimulation at home: aerobic physical activity and 
specific but simple cognitive activities every day. Level 3 
was introduced to improve in the amount and intensity of the 
MST treatment and to favor a positive PWA–caregiver inter-
action at home (eg, strategies of practical coping solutions).
Procedures
As shown in timeline (Figure 1), assessments were done in 
both groups at baseline (T_0) and after 10 weeks (T_1). 
Only in the tMST group a follow-up evaluation was col-
lected after 22 weeks, because the ntMST group was treated 
with MST for ethical purposes in accordance with the rec-
ommendations of the local ethics committee.
The tools used as primary outcome measures in this trial 
were the following: (a) Alzheimer’s Disease Assessment 
Scale–Cognitive subscale (ADAS-cog31); (b) the 
Functional Living Skills Assessment Scale (FLSA32); (c) 
the Neuropsychiatric Inventory scale (NPI33); and (d) qual-
ity of life measures (Short Form 36 health survey question-
naire—SF-3634). Changes in cognitive (ADAS-cog), 
Table 1. Baseline Demographics, Neuropsychological, and Anatomical Characteristics.
tMST Participants ntMST Participants Group Comparisona
Demographic characteristics
 Age, years (mean ± SD) 75.61 ± 5.86 76.50 ± 5.65 ns
 Gender (male–female) 13:15 10:14 ns
 Level of education, years (mean ± SD) 8.61 ± 3.75 9.43 ± 4.42 ns
 CDR, median [range] 1.5 [1-2] 1.5 [1-2] ns
 MMSE (mean ± SD) 21.54 ± 3.78 22.04 ± 2.61 ns
 NPI 15.70 ± 11.21 14.28 ± 8.50 ns
Anatomical characteristics
 Left hippocampal volume (mm3) 2751 ± 526 2704 ± 449 ns
 Right hippocampal volume (mm3) 2806 ± 580 2960 ± 558 ns
Abbreviations: tMST, people treated with Multidimensional Stimulation group Therapy; ntMST, people with usual care program; CDR, Clinical 
Dementia Rating scale; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory scale.
aSociodemographic and neuropsychological variables were compared at baseline using t test or χ2 as appropriate. Data are relative to PWA who 
completed the trial (52 subjects).
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functional (FLSA), behavioral (NPI) status, and in physical 
well-being (SF-36) were assessed by an experienced neu-
ropsychologist blinded to the treatment.
Finally, we used fMRI with a language task (paced-overt 
verbal fluency task35) to detect possible changes (T1 vs T0) 
in brain activation patterns in PWA as a surrogate biomarker 
of MST efficacy.
MRI Acquisition Protocol. MRI scans were obtained using a 
1.5-Tesla scanner (Magnetom Avanto, Siemens). The protocol 
included the following: (a) a structural MRI study with T1, 
T2, and FLAIR weighted images to exclude subjects with 
pathological brain abnormality; (b) fMRI echo planar images 
with blood oxygenation level dependent (BOLD) contrast; 
and (c) a morphological T1-weighted MPRAGE sequence, 
used as reference for fMRI analysis and for the calculation of 
structural measures (hippocampal volumes) with FSL 
(FMRIB’s Software Library; www.fmrib.ox.ac.uk/fsl).
fMRI Stimuli/Design. We adopted the verbal fluency para-
digm described by Basho and colleagues35 to test language 
function. This fMRI task was chosen because it allows an 
appropriate response monitoring and a tight control over 
and reduced individual variability of task performance, 
making it suitable for the application in patients with cogni-
tive deficits. The functional sequence included 6 experi-
mental blocks alternated with 6 control blocks (30 seconds 
for block) for a total duration of 6 minutes (see Supplemen-
tal Methods for details, available online at http://nnr.sage-
pub.com/content/by/supplemental-data).
Before the fMRI session, all participants completed a 
practice session, which included different stimuli from 
those presented in the scanner. For stimuli presentation and 
overt responses collection, we used an MRI-compatible 
visual and sound system (VisuaStim Digital system from 
Resonance Technology Inc), while the use of E-Prime soft-
ware 2.0 (http://www.pstnet.com) ensured exact timing of 
prompts.
Statistical Analysis
Statistical analysis on primary outcome measures was per-
formed using SAS software package 9.2. Sociodemographic, 
clinical, and neuropsychological variables were compared 
at baseline using t test or χ2 test as appropriate.
The primary outcome measures in this study were 
changes in neuropsychological test and scale scores from 
baseline. We modeled these changes at 10 weeks. Only in 
the tMST group there were changes also evaluated at 22 
weeks. To account for variable skewness, nonparametric 
analysis and variables normalization using Blom’s transfor-
mation were performed. Mann–Whitney nonparametric 
comparison of score differences was performed to identify 
statistically significant results. When variables resulted in a 
statistically significant difference, the analysis was con-
firmed using the analysis of covariance of normalized 
scores. Score differences were described using mean and 
standard deviation of retro-transformed Blom’s variables. 
Categorical variables were described by percentages. The 
least square differences and R2 model fitting were reported 
in Table 2. An α value of .05 was considered statistically 
significant, and all comparisons were 2-tailed. Finally, 
score modifications at 22 weeks in the tMST group were 
evaluated by means of regression analysis over time consid-
ering previous values at baseline and 10 weeks.
fMRI Data Analysis
To investigate for fMRI task performance differences 
between groups at baseline and at 10 weeks, a logistic 
Figure 1. Timeline of the trial. Timing and duration of the various procedures used in the trial.
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analysis was performed where percentages of correct task 
was the response variable and group by time interaction an 
explanatory covariate. To account for over dispersion of 
the response, the Williams scaling criterion was applied.
Statistical analysis on fMRI data was performed using 
SPM8 (http://www.fil.ion.ucl.ac.uk/spm). Images were 
realigned, coregistered, normalized (MNI space), and spa-
tially smoothed. Single subject statistical analysis (first 
level) was then performed with a general linear model 
(GLM) to detect the activation areas during the task (t-con-
trast: categorical-fluency vs control-condition). The corre-
sponding contrast images (1 image for each subject, 
obtained as the product between the GLM parameter esti-
mates–betas–and the contrast vector) entered in the group 
analyses (second level).
First, to describe the main effect of the language task 
(typical activation pattern) and to extract regions of interest 
(ROIs) running Marsbar (http://marsbar.source-forge.net/) 
to be used as a priori ROIs for subsequent analyses on PWA 
(see below), we performed a 1-sample t test in the HC group 
(supplemental Figure S1 and Table S1).
The following second-level analyses were then per-
formed in PWA: (a) 1-sample t tests in the PWA (both tMST 
and ntMST) at T_0 to describe the main effect of the lan-
guage task at baseline; (b) 1-sample t tests in the PWA (both 
tMST and ntMST) at T_1 to describe the main effect of the 
language task after 10 weeks; (c) a flexible-factorial analy-
sis including 3 factors (subject definition; group [tMST or 
ntMST]; time [T_0 or T_1]) to test the effect of treatment 
(tMST vs ntMST, group-by-time interaction: contrast 1: 
tMST [T_1 > T_0] > ntMST [T_1 > T_0]; contrast 2: ntMST 
[T_1 > T_0] > tMST [T_1 > T_0]). Normalized grey matter 
volume was included as a covariate. The maps resulting 
from the second-level analyses on PWA were thresholded 
with 2 approaches: first, we performed a statistical analysis 
within the ROIs identified in the control group by using cor-
rection for multiple comparisons (family-wise error [FWE], 
P < .05); then, for exploratory purposes, nonhypothesized 
group differences outside the ROIs were described consid-
ering an uncorrected P < .001 threshold with 10 or more 
contiguous voxels.
Finally, to investigate the relationship between changes 
in behavior and changes in magnitude of activation in tMST 
compared to ntMST, we performed an additional regression 
analysis considering score changes by groups. For each 
PWA we generated a single contrast map (T_1 > T_0) and 
we extracted the mean beta value within the 10 ROIs identi-
fied as critical for language functioning in the control group 
(see Table S2) running Marsbar tool (http://marsbar.source-
forge.net/). Then, we plotted ADASCog delta score (T_1 
minus T_0 scores) against the beta values for all PWA sub-
jects by groups in a linear regression analysis.
Results
The statistical analyses consisted of 28 PWA given MST 
and 24 given standard treatment of care (Figure 2). The 2 
groups were similar at baseline in sociodemographic char-
acteristics (age P = .58; gender P = .95; education level P = 
.47), global cognitive level (MMSE, P = .58), and brain hip-
pocampal volumes (left hippocampus P = .76; right hippo-
campus P = .38; Table 1).
Neuropsychological and Behavioral Results
The results obtained by PWA and the comparison between 
the 2 groups (tMST vs ntMST) on test and scales are sum-
marized in Table 2. Behavioral symptoms showed a signifi-
cant reduction in tMST with respect to ntMST (NPI global 
score P = .019). The tMST group also obtained a significant 
improvement in language (spoken language P = .01; nam-
ing objects and fingers P = .004) and memory (word recall 
P = .045; remembering test instructions P = .041) subscales 
of ADAS-Cog. No statistically significant differences 
between baseline and T_1 were observed in the measures of 
functional status (FLSA P = .649) and physical well-being 
(SF-36 MCS P = .83; SF-36 PCS P = .99).
Finally, we obtained no statistically significant slope of 
the regression model for any of the previous described 
Table 2. Analysis of Covariance Results for All Test/Scales and 
Statistically Significant Subscales of ADAS-Cog.
Test and Subscales tMST ntMST P Value
Alzheimer’s Disease Assessment Scale
Global scorea 22.3 (0.66) 23.6 (0.83) .344
 Word recallb 1.16 (0.10) 1.41 (0.11) .045
 Naming objects and 
fingersa,b
1.07 (0.10) 1.48 (0.11) .004
 Remembering test 
instruction
1.13 (0.10) 1.45 (0.11) .061
Spoken languageb 0.89 (0.13) 1.27 (0.14) .010
Functional Living Skills Assessment
 Global scorea 99.6 (1.52) 98.5 (1.69) .649
Neuropsychiatric Inventory Scale
 Global scorea 13.2 (1.14) 17.5 (1.35) .019
 Distress global score 6.9 (0.55) 8.6 (0.65) .054
Short Form-36 health survey questionnaire
 Mental component 
scale
43.4 (1.37) 43.9 (1.59) .830
 Physical component 
scale
47.6 (1.23) 47.5 (1.42) .992
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale; tMST, 
people treated with Multidimensional Stimulation group therapy; ntMST, 
people with usual care program.
Statistically significant P Values (P <0.05) were reported in italics.
aModel R2 > 0.60.
bMann–Whitney U-test P < .05.
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cognitive (language and memory subscale of ADAS-Cog) 
and behavioral (NPI values) measures considered in the 
tMST group at 22 weeks with respect to baseline and 10 
weeks results.
fMRI Results
Regarding fMRI, only data relative to 22 PWA (12 tMST 
and 10 ntMST) entered the second-level fMRI analyses (the 
details of this subsample are shown in Supplemental results 
and Table S2). The task performance of the included sub-
jects on correct responses was 83.1% to 84.2% (tMST-
ntMST) at baseline and 88.9% to 87.8 % (tMST-ntMST) 
after 10 weeks. The fMRI task performance differences 
within group (tMST P = .37; ntMST P = .70) and between 
groups at baseline and 10 weeks were not statistically sig-
nificant (P = .47).
In line with previous findings,35,36 the healthy controls 
exhibited a typical activation pattern of paced overt verbal flu-
ency task: areas related to category-driven word generation 
(left inferior and middle frontal cortex, the superior and 
middle temporal regions, left thalamus and lentiform nucleus), 
areas associated with paced response and overt articulation 
(cingulate cortex, right superior parietal cortex, insular cortex, 
thalamus, lentiform nucleus and cerebellum; see supplemen-
tal Figure S1 and Table S1 for details). These clusters were 
chosen as a priori ROIs for subsequent analyses.
As shown in Figure 3A, a significant activation (P
FWE
 < 
.05) in PWA was found at T_0 only in the left superior tem-
poral gyrus (BA 22). For exploratory purposes, considering 
an uncorrected threshold P < .001 with 10 or more contigu-
ous voxels, we found brain activations also in the left infe-
rior frontal (BA 44) gyrus.
At T_1 (Figure 3B), the activation pattern found at base-
line was strongly increased, resulting in significant activa-
tions (P
FWE
 < .05) in the left inferior frontal and superior 
temporal gyri, the right superior temporal cortex (BA 
22-41), the left cingulate cortex (BA32), the bilateral basal 
ganglia, thalamus, and the right superior parietal lobule (BA 
7). Considering an uncorrected threshold P < .001 with 
more than 10 contiguous voxels, we found an additional 
brain activation in the right cerebellum.
Results of the flexible factorial analysis evaluating the 
effect of treatment (group-by-time interaction) are reported 
in Table 3: the tMST group showed a significant interven-
tion-related increase in activation (contrast 1: tMST [T_1 > 
T_0] > ntMST [T_1 > T_0], P
FWE
 < .05) of the bilateral 
superior temporal gyrus (right > left) and the right lentiform 
nucleus and thalamus. Considering an uncorrected thresh-
old P < .001 with more than 10 contiguous voxels, we 
observed in the tMST group an additional increase in brain 
activation in the right insular cortex with respect to the 
ntMST due to the MST intervention. No significant activa-
tion were found with the opposite contrast (contrast 2: 
ntMST [T_1 > T_0] > tMST [T_1 > T_0]). The plots in 
Figure 4 illustrate the mean beta values for each group 
(ntMST and tMST) at T_0 and T_1 extracted from the 4 
clusters described in Table 3.
Finally, the results of regression analysis are reported in 
Figure 5. In the tMST group we found a significant correla-
tion between increase in magnitude of activation in the left 
superior temporal gyrus (BA 22/41—ROI 2), precuneus 
(BA7—ROI 5), left thalamus (ROI 9), and change in 
ADAS-Cog. Conversely, only one significant correlation 
was found in ntMST group between the left superior tempo-
ral gyrus (ROI 2) and change in ADAS-Cog. The negative 
correlation is due to the ADAS-Cog score: a decrease in 
ADAS-Cog score is indicative of cognitive improvement.
Discussion
The results obtained in this RCT study supported the initial 
hypothesis that MST has an impact on at least 2 AD 
domains: behavior-reduction of BPSD and improvement in 
some cognitive abilities.
Figure 2. Trial profile.
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Regarding the behavioral domain, these results confirm 
our previous findings24,25 and are in line with other non-
pharmacological studies that reported a reduction of BPSD 
with the single components of our therapy.37-41 MST can 
be easily implemented with both ambulatory patients, 
such as in our case, and institutionalized ones and applies 
to people with BPSD in the moderate range. As severe 
psychotic symptoms (hallucinations, significant delu-
sions, or evident aggression) would preclude the 
participation in group therapy, we did not include this type 
of PWA in this study. Examining the single items of NPI, 
we observed that the BPSD which benefit most from MST 
were depression, anxiety, irritability, and aberrant motor 
behavior. Teri and her group37 observed a decrease of 
depression in PWA after a treatment based on physical 
activity. Interestingly, different mechanisms were recently 
suggested to support the notion that exercise may have the 
potential to slow the decline of AD.19,42 There is the pos-
sibility that new brain cells can be created within the criti-
cal parts of the hippocampus in PWA who are physically 
fit. There is also the possibility that increased neural con-
nectivity can be obtained through the neuroplastical activ-
ity of BDNF, whose levels appear to be increased by 
exercise.43 Gitlin et al have reported38,39 a reduction of 
BPSD as a result of an occupational therapy intervention 
with empowerment of caregiver coping abilities. They 
also showed that nonpharmacologic management of BPSD 
is a recommended, cost-effective treatment as it can sig-
nificantly improve quality of life and patient–caregiver 
satisfaction.15 Reduction of apathy, a BPDS symptom very 
difficult to treat, has been reported with an occupational 
therapy approach,40 and even more “cognitive-oriented” 
techniques.44 However, we believe that MST, a multidi-
mensional treatment including all of these techniques, is 
the most suitable to obtain positive results, in concordance 
with Arkin’s opinion: “Clinically, there is much to be said 
for leaving the combined intervention intact. By offering a 
Figure 3. Main effect of paced-overt verbal fluency task in PWA: brain areas showing a significant activation at baseline (A) and after 
10 weeks (B).
Data are relative to PWA (both tMST and ntMST) who completed the 2 fMRI assessments (N = 22; P
FWEcorrected
 < .05; MRI coordinate 62;-18;2).
Abbreviations: PWA, people with Alzheimer’s disease; tMST, people treated with multidimensional stimulation group therapy; ntMST, people with 
usual care program; R, right hemisphere.
Table 3. Maxima of Regions Showing Significantly Higher Brain 
Activation From T_0 to T_1 in tMST Group With Respect to 




Size Side Brain Area BA z-Value  
−50 −32 8 18 L Sup temporal Gy 41_22 3.48 *
58 −10 8 81 R Sup temporal Gy 41_22 3.57 *
44 −32 18 15 R Insula 13 3.57  
16 − 8 0 42 R Thalamus — 4.28 *
Abbreviations: Sup, superior; Inf, inferior; R, right; L, left; Gy, gyrus; BA, Brodmann 
area; tMST, people treated with multidimensional stimulation group therapy; 
ntMST, people with usual care program; fMRI, functional magnetic resonance 
imaging; ROI, region of interest.
aFlexible factorial analysis (group per factor interaction). Data are relative to PWA 
(both tMST and ntMST) who completed the 2 fMRI assessments (N = 22).
bResults are relative to P < .001 uncorrected.
*Clusters FWE corrected for multiple comparisons within the ROIs extracted 
from the control group.
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variety of activities, you are providing multiple and differ-
ent opportunities for participants to be successful.”21 
Moreover, we are now well aware of the possible side 
effects and risks of psychotropic medications in PWA. 
Consequently, nonpharmacological interventions have 
become the first-line approach for BPSD.15,41 In this per-
spective, the MST approach can be helpful to avoid the 
excessive use of these drugs for BPSD.
As far as the cognitive domain is concerned, we found 
an improvement of language and memory ADAS-Cog 
subscales. This is in line with a recent study by Hall and 
colleagues13 investigating the effects of CST9 on specific 
areas of cognition. They attribute the changes in language 
and memory to the language-based nature of CST that 
enhances neural pathways responsible for processing of 
syntax, possibly aiding also verbal recall. Moreover, they 
hypothesize that these CST-induced changes promote the 
functioning of alternative neural pathways.45 As with 
CST,12 our MST was group-based and included, in the first 
step of level 1 (Reality Orientation activities and cognitive 
exercises), many tasks aimed to reinforce oral and written 
language. Furthermore, group therapy has been shown to 
facilitate social interaction among participants and to con-
sequently promote language function,46 thereby reducing 
the additional handicap due to social isolation of PWA.17 
For the first time, we are able to discuss also the neural 
mechanisms that may underlie these intervention-related 
changes on language by using fMRI. The fMRI results at 
T_1 with respect to T_0 showed increased brain activation 
in left frontotemporal areas (BA 22/44), right superior 
temporal cortex, bilateral basal ganglia, cingulate cortex, 
and right superior parietal cortex. In the tMST group, an 
intervention-related increase in activations was found in 
the bilateral superior temporal cortex (BA 22/41), the thal-
amus, and the anterior insular cortex. It is known that 
thalamus and basal ganglia play an important role in word 
generation, and recent data suggest that the thalamus acts 
as a central monitor for language-specific cortical activi-
ties, supported by the basal ganglia in both perceptual and 
productive language execution.47 Moreover, the insular 
cortex plays an important role in speech and emotional 
experience, and it has been demonstrated that hypome-
tabolism of the anterior insula is associated with progres-
sive nonfluent aphasia.48 Furthermore, MRI studies have 
shown that the insula is interconnected with the temporal 
and orbitofrontal cortices and inferior frontal gyrus.49 The 
obtained fMRI intervention-related changes may reflect a 
restoration of neural function in the underactive language 
Figure 4. Plots show mean beta values for each group (ntMST and tMST) at baseline (T_0) and after 10 weeks (T_1) extracted from 
the 4 clusters refer to contrast: tMST (T_1 > T_0) > ntMST (T_1 > T_0) (see Table 3).
Error bars indicate the standard error of the mean.
Abbreviations: tMST, people treated with multidimensional stimulation group therapy; ntMST, people with usual care program.
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network via the compensatory strengthening of specific 
brain regions.45 Further intervention-related changes, 
although using an encoding-recognition task, were 
described using fMRI by Clare and colleagues.6 They per-
formed an RCT on cognitive rehabilitation in people with 
dementia and a subset of participants also underwent fMRI 
scanning. Four right brain regions forming part of the net-
work for visual associative learning (fusiform face area, 
medial prefrontal gyrus, parahippocampal cortex, and 
temporal parietal junction) showed increased activation 
due to the treatment and the authors inferred that these 
results primarily reflect restoration of function in PWA.
The changes we saw in fMRI support the notion that 
even the AD brain still has plasticity resources and can react 
to positive environmental stimuli. Obviously, intervention 
in the predementia stage could improve the memory domain 
even more so, assuming that the more precocious the 
cognitive intervention is, the better the result will be. In this 
perspective, it is interesting to note that some recent studies 
reported increased hippocampal activity after memory 
training in MCI people, suggesting that the hippocampus 
may retain sufficient neuroplasticity in this clinical situa-
tion.50,51 However, even if this will probably be the right 
strategy in the future, our study, along with others,13,22,39 
demonstrates that cognitive stimulation can be useful in 
people with overt AD.
Regarding the long-lasting effect of the treatment, our 
data showed that the improvement in cognitive and behav-
ioral areas is preserved at 22 weeks. The persistence of 
effects, along with generalization of gain in everyday life, is 
the critical point of nonpharmacological therapies and is 
being explored in ongoing trials.11 The necessity of a long-
term treatment to maintain positive effects engenders the 
problem of the treatment costs. However, it must 
Figure 5. Scatterplots show statistically significant results of regression analysis considering score changes by groups.
We plot ADAS-Cog delta score (T_1 minus T_0) against the betas values (T_1 > T_0) for all PWA subjects by groups (tMST, ntMST).
Abbreviations: tMST, people treated with multidimensional stimulation group therapy; ntMST, people with usual care program; ROI region of interest.
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be considered that MST is a group treatment, potentially 
allowing for a more effective use of personnel resources 
when compared to individual-specific techniques. 
Moreover, relatives and caregivers assisting PWA at home 
can be trained for this type of treatment to reinforce and 
make the benefits more enduring.24
We consider the differences in cognition and behavior 
are clinically meaningful. PWA in the treated group showed 
a reduction of BPSD of almost 20% from the baseline 
level. Moreover, this result was due above all to reduction 
of symptoms such as depression, irritability, and aberrant 
motor behavior, which have a particular negative impact on 
caregivers in our clinical experience.52 We consider this 
result clinically significant, because it can allow a reduc-
tion of the use of antipsychotic drugs, whose harmful 
effects on PWA is now well known. As for the clinical 
value of results in the cognitive domain, we believe that 
obtaining even a moderate improvement of language and 
memory is a meaningful result: memory impairment is the 
principal symptom of PWA and is a source of depression 
for them and of burden for caregivers (eg, due to repetitive 
questioning)53; impairment of language, on the other hand, 
favors social isolation and has particular negative sequelae 
for the interaction with family members, increasing their 
burden of care. In the progression from moderate to severe 
stages in AD, worsening language abilities, or aphasia, has 
been suggested to have more clinical relevance than other 
domains. As a matter of fact, decline in language has been 
shown to correlate with noncognitive items, such as per-
sonal care, hobbies, occupations, and behavior.53
Overall, despite the significant results in improving dif-
ferent aspects of PWA, our study is not without limitations. 
Although the improvement in cognitive and behavioral 
areas was preserved in the tMST group at 22 weeks, the 
length of follow-up was relatively short. Thus, whether or 
not the treatment effect produced by the MST approach is 
long-lasting remains unknown at this time. Future studies 
should investigate MST’s efficacy over longer durations of 
time. Furthermore, a direct comparison between the tMST 
and ntMST groups at T_2 was not possible due to ethical 
concerns. Our ethical committee requested that we also 
treat the ntMST group after T_1 evaluation.
In conclusion, MST is a nonpharmacological approach 
for mild to moderate PWA that was shown to have a positive 
impact on behavioral and cognitive functions, enhancing 
patients’ motivation, promoting the use of their remaining 
function, and preventing further loss in agreement with the 
statement “use it or lose it.”54
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with 
respect to the research, authorship, and/or publication of this 
article.
Funding
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: This 
work was supported by 2011-2012 Ricerca Corrente (Italian 
Ministry of Health).
References
 1. McKhann GM, Knopman DS, Chertkow H, et al. The diagno-
sis of dementia due to Alzheimer’s disease: recommendations 
from the National Institute on Aging-Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease. 
Alzheimers Dement. 2011;7:263-269.
 2. Farina E. The language revolution—editorial. Nonpharmacol 
Ther Dement. 2012;2(2):77-80.
 3. Moniz-Cook E, Vernooij-Dassen M, Woods B, Orrell M. 
Psychosocial interventions in dementia care research: the 
INTERDEM manifesto. Aging Ment Health. 2011;15: 
283-290.
 4. Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuro-
plasticity for clinical applications. Brain. 2011;134(pt 6): 
1591-1609.
 5. Hampstead BM, Stringer AY, Stilla RF, et al. Activation and 
effective connectivity changes following explicit-memory 
training for face-name pairs in patients with mild cogni-
tive impairment: a pilot study. Neurorehabil Neural Repair. 
2011;25:210-222.
 6. Clare L, Linden DE, Woods RT, et al. Goal-oriented cognitive 
rehabilitation for people with early-stage Alzheimer disease: 
a single-blind randomized controlled trial of clinical efficacy. 
Am J Geriatr Psychiatry. 2010;18:928-939.
 7. Aguirre E, Hoare Z, Streater A, et al. Cognitive stimulation 
therapy (CST) for people with dementia—who benefits most? 
Int J Geriatr Psychiatry. 2013;28:284-290.
 8. Spector A, Davies S, Woods B, Orrell M. Reality orientation 
for dementia: a systematic review of the evidence of effec-
tiveness from randomized controlled trials. Gerontologist. 
2000;40:206-212.
 9. Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an 
evidence-based cognitive stimulation therapy programme 
for people with dementia: randomised controlled trial. Br J 
Psychiatry. 2003;183:248-254.
 10. National Institute for Health and Clinical Excellence and the 
Social Care Institute for Excellence (NICE-SCIE). A NICE–
SCIE Guideline on Supporting People With Dementia and 
Their Carers in Health and Social Care (National Clinical 
Practice Guideline No. 42). London, England: British 
Psychological Society & Royal College of Psychiatrists; 2007.
 11. Streater A, Spector A, Aguirre E, et al. Maintenance cogni-
tive stimulation therapy (CST) in practice: study protocol for 
a randomized controlled trial. Trials. 2012;13:91.
 12. Spector A, Orrell M, Woods B. Cognitive stimulation ther-
apy (CST): effects on different areas of cognitive function 
for people with dementia. Int J Geriatr Psychiatry. 2010;25: 
1253-1258.
 13. Hall L, Orrell M, Stott J, Spector A. Cognitive stimulation 
therapy (CST): neuropsychological mechanisms of change. 
Int Psychogeriatr. 2013;25:479-489.
Baglio et al 23
 14. Woods B, Aguirre E, Spector AE, Orrell M. Cognitive 
stimulation to improve cognitive functioning in people with 
dementia. Cochrane Database Syst Rev. 2012;(2):CD005562.
 15. Gitlin LN, Hodgson N, Jutkowitz E, Pizzi L. The cost-effec-
tiveness of a nonpharmacologic intervention for individuals 
with dementia and family caregivers: the tailored activity 
program. Am J Geriatr Psychiatry. 2010;18:510-519.
 16. Kolanowski A, Litaker M, Buettner L, Moeller J, Costa PT Jr. 
A randomized clinical trial of theory-based activities for the 
behavioral symptoms of dementia in nursing home residents. 
J Am Geriatr Soc. 2011;59:1032-1041.
 17. Teri L, Logsdon RG, McCurry SM. Exercise interventions for 
dementia and cognitive impairment: the Seattle protocols. J 
Nutr Health Aging. 2008;12:391-394.
 18. Thune-Boyle IC, Iliffe S, Cerga-Pashoja A, Lowery D, 
Warner J. The effect of exercise on behavioral and psycho-
logical symptoms of dementia: towards a research agenda. Int 
Psychogeriatr. 2012;24:1046-1057.
 19. Erickson KI, Voss MW, Prakash RS, et al. Exercise training 
increases size of hippocampus and improves memory. Proc 
Natl Acad Sci U S A. 2011;108:3017-3022.
 20. Probst M, Knapen J, Poot G, Vancampfort D. Psychomotor 
therapy and psychiatry: what’s in a name? Open Complement 
Med J. 2010;2:105-113.
 21. Arkin S. Language-enriched exercise plus socialization slows 
cognitive decline in Alzheimer’s disease. Am J Alzheimers 
Dis Other Demen. 2007;22:62-77.
 22. Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological 
therapies in Alzheimer’s disease: a systematic review of effi-
cacy. Dement Geriatr Cogn Disord. 2010;30:161-178.
 23. Farina E, Fioravanti R, Chiavari L, et al. Comparing two pro-
grams of cognitive training in Alzheimer’s disease: a pilot 
study. Acta Neurol Scand. 2002;105:365-371.
 24. Farina E, Mantovani F, Fioravanti R, et al. Evaluating two group 
programmes of cognitive training in mild-to-moderate AD: is 
there any difference between a “global” stimulation and a “cog-
nitive-specific” one? Aging Ment Health. 2006;10:211-218.
 25. Farina E, Mantovani F, Fioravanti R, et al. Efficacy of 
recreational and occupational activities associated to psy-
chologic support in mild to moderate Alzheimer disease: a 
multicenter controlled study. Alzheimer Dis Assoc Disord. 
2006;20:275-282.
 26. Magni E, Binetti G, Bianchetti A, Rozzini R, Trabucchi M. 
Mini-Mental State Examination: a normative study in Italian 
elderly population. Eur J Neurol. 1996;3:198-202.
 27. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A 
new clinical scale for the staging of dementia. Br J Psychiatry. 
1982;140:566-572.
 28. Oldfield RC. The assessment and analysis of handedness: the 
Edinburgh Inventory. Neuropsychologia. 1971;9:97-113.
 29. Spinnler H, Tognoni P. Standardizzazione e taratura italiana 
di test neuropsicologici. Ital J Neurol Sci. 1987;86:1-20.
 30. Wood W, Harris S, Snider M, Patchel SA. Activity situations 
on an Alzheimer’s disease special care unit and resident envi-
ronmental interactions, time use, and affect. Am J Alzheimers 
Dis Other Demen. 2005;20:105-118.
 31. Rosen WG, Mohs RC, Davis KL. A new rating scale for 
Alzheimer’s disease. Am J Psychiatry. 1984;141:1356-1364.
 32. Farina E, Fioravanti R, Pignatti R, et al. Functional liv-
ing skills assessment: a standardized measure of high-order 
activities of daily living in patients with dementia. Eur J Phys 
Rehabil Med. 2010;46:73-80.
 33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson 
S, Carusi DA, Gornbein J. The neuropsychiatric inventory: 
comprehensive assessment of psychopathology in dementia. 
Neurology. 1994;44:2308-2314.
 34. Apolone G, Mosconi P. The Italian SF-36 health survey: 
translation, validation and norming. J Clin Epidemiol. 
1998;51:1025-1036.
 35. Basho S, Palmer ED, Rubio MA, Wulfeck B, Muller 
RA. Effects of generation mode in fMRI adaptations of 
semantic fluency: paced production and overt speech. 
Neuropsychologia. 2007;45:1697-1706.
 36. Price CJ. A review and synthesis of the first 20 years of PET 
and fMRI studies of heard speech, spoken language and read-
ing. Neuroimage. 2012;62:816-847.
 37. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behav-
ioral management in patients with Alzheimer disease: a ran-
domized controlled trial. JAMA. 2003;290:2015-2022.
 38. Gitlin LN, Winter L, Burke J, Chernett N, Dennis MP, Hauck 
WW. Tailored activities to manage neuropsychiatric behaviors in 
persons with dementia and reduce caregiver burden: a random-
ized pilot study. Am J Geriatr Psychiatry. 2008;16:229-239.
 39. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. 
A biobehavioral home-based intervention and the well-being 
of patients with dementia and their caregivers: the COPE ran-
domized trial. JAMA. 2010;304:983-991.
 40. Buettner L, Fitzsimmons S. Recreational therapy interven-
tions: a fresh approach to treating apathy and mixed behaviors 
in dementia. Nonpharmacol Ther Dement. 2011;1(1):27-42.
 41. Corbett A, Smith J, Creese B, Ballard C. Treatment of behav-
ioral and psychological symptoms of Alzheimer’s disease. 
Curr Treat Options Neurol. 2012;14:113-125.
 42. Exercise and brain health. Preventing Alzheimer’s and more. 
Mayo Clin Health Lett. 2013;31(1):4-5.
 43. Erickson KI, Voss MW, Prakash RS, et al. Exercise training 
increases size of hippocampus and improves memory. Proc 
Natl Acad Sci U S A. 2011;108:3017-3022.
 44. Vallar G, Cantagallo A, Cappa SF, Zoccolotti P. La riabili-
tazione neuropsicologica un’analisi basata sul metodo evi-
dence-based medicine. Berlin, Germany: Springer; 2012.
 45. Stern Y. What is cognitive reserve? Theory and research 
application of the reserve concept. J Int Neuropsychol Soc. 
2002;8:448-460.
 46. Spector A, Gardner C, Orrell M. The impact of cognitive 
stimulation therapy groups on people with dementia: views 
from participants, their carers and group facilitators. Aging 
Ment Health. 2011;15:945-949.
 47. Klostermann F, Krugel LK, Ehlen F. Functional roles of 
the thalamus for language capacities. Front Syst Neurosci. 
2013;16(7):32.
 48. Jakab A, Molnar PP, Bogner P, Beres M, Berenyi EL. 
Connectivity-based parcellation reveals interhemispheric dif-
ferences in the insula. Brain Topogr. 2012;25:264-271.
 49. Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, 
Hodges JR. Progressive non-fluent aphasia is associated with 
24 Neurorehabilitation and Neural Repair 29(1)
hypometabolism centred on the left anterior insula. Brain. 
2003;126(pt 11):2406-2418.
 50. Hampstead BM, Stringer AY, Stilla RF, Giddens M, Sathian 
K. Mnemonic strategy training partially restores hippo-
campal activity in patients with mild cognitive impairment. 
Hippocampus. 2012;22:1652-1658.
 51. Rosen AC, Sugiura L, Kramer JH, Whitfield-Gabrieli 
S, Gabrieli JD. Cognitive training changes hippocampal 
function in mild cognitive impairment: a pilot study. J 
Alzheimers Dis. 2011;26(suppl 3):349-357.
 52. Sink KM, Holden KF, Yaffe K. Pharmacological treatment 
of neuropsychiatric symptoms of dementia: a review of the 
evidence. JAMA. 2005;293:596-608.
 53. Woodward M. Aspects of communication in Alzheimer’s dis-
ease: clinical features and treatment options. Int Psychogeriatr. 
2013;25:877-885.
 54. Swaab DF, Dubelaar EJ, Hofman MA, Scherder EJ, van 
Someren EJ, Verwer RW. Brain aging and Alzheimer’s 
disease: use it or lose it. Prog Brain Res. 2002;138: 
343-373.
